Apellis Pharmaceuticals announces plan to slash workforce by 25%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Raymond James Reiterates Strong Buy Rating on Apellis Pharmaceuticals (APLS), 'a signal of commitment to and confidence in Syfovre'
August 29, 2023 3:16 PM EDTRaymond James analyst Steven Seedhouse reiterated a Strong Buy rating and $89.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)
The analyst comments "We remain at a Strong Buy rating on APLS following an announced cost savings program. Apellis restructuring announcement sends an interesting signal at an... More
Apellis Pharmaceuticals (APLS) PT Raised to $54 at Citi, 'Corporate Restructuring Not Overly Surprising'
August 29, 2023 3:15 PM EDTCiti analyst Yigal Nochomovitz raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $54.00 (from $45.00) while maintaining a Buy rating.
The analyst comments "We are inferring based on timing of restructuring that Apellis revised internal projections for the Syfovre launch following the ROV disclosures are... More
